Chemiluminescence Immunoassay Market Size & Growth Forecast 2027–2036, By Segments (Product, Sample Type, End-use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Chemiluminescence Immunoassay Market size was more than USD 12.85 billion in 2026 and is set to grow at a 4.37% CAGR between 2027 and 2036, surpassing USD 19.71 billion by 2036. The industry revenue for 2027 is assessed at USD 13.32 billion.
Get more details on this report
Request Free Sample ReportChemiluminescence Immunoassay Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 43.14% share in 2026, supported by mature laboratory infrastructure, automated diagnostic systems, and high-volume testing across healthcare facilities.
- Asia Pacific is projected to grow at a 5.47% CAGR as laboratories expand diagnostic capacity and adopt automated, higher-throughput testing platforms.
Segment Momentum
- Consumables accounted for 64.21% of the market in 2026 because reagents, assay kits, calibrators, and controls are required for every test cycle, creating continuous demand linked to testing volumes.
- Urine is gaining traction because non-invasive collection improves convenience and accessibility, helping laboratories and healthcare providers expand screening activities without increasing sample acquisition complexity.
Market Expansion Drivers
- Rising prevalence of infectious and chronic diseases driving demand for advanced diagnostic testing.
- Expanding hospital laboratory automation increasing adoption of high-throughput immunoassay platforms.
- High diabetes and cancer screening rates boosting routine diagnostic testing volumes globally.
Leading Market Participants
- Leading companies in the chemiluminescence immunoassay market include Abbott Laboratories (United States), F. Hoffmann-La Roche AG (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (United States), DiaSorin S.p.A. (Italy), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Sysmex Corporation (Japan), bioMérieux SA (France), QuidelOrtho Corporation (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 12.85 billion
- 2027 Estimated Market Size: USD 13.32 billion.
- Projected Market Size: USD 19.71 billion by 2036
- Growth Forecast: 4.37% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Consumables (Product) | Blood (Sample Type) | Hospitals (End-use) | Infectious Disease (Application)
- Emerging Opportunity Segment: Consumables (Product) | Urine (Sample Type) | Pharmaceutical & Biotechnology Companies (End-use) | Oncology (Application)
Market Growth Drivers and Industry Trends
Rising prevalence of infectious and chronic diseases driving demand for advanced diagnostic testing
The increasing burden of infectious and chronic diseases is creating sustained demand for the chemiluminescence immunoassay market as healthcare systems require reliable diagnostic methods for disease detection and monitoring. Chemiluminescence-based testing offers sensitive analytical capabilities across a broad range of clinical applications, allowing laboratories to evaluate relevant biomarkers and disease indicators. As healthcare providers manage a wider range of diagnostic requirements, advanced immunoassay platforms are becoming increasingly important within clinical laboratory workflows.
Expanding hospital laboratory automation increasing adoption of high-throughput immunoassay platforms
Expansion of laboratory automation is contributing to the chemiluminescence immunoassay market as hospitals seek to process larger volumes of diagnostic samples with greater consistency and operational efficiency. Automated immunoassay platforms can streamline sample handling, testing, and result generation while reducing the need for extensive manual intervention. High-throughput capabilities are particularly valuable in hospital laboratories managing continuous diagnostic workloads, supporting broader integration of automated immunoassay technologies into routine laboratory operations.
High diabetes and cancer screening rates boosting routine diagnostic testing volumes globally
High levels of diabetes and cancer screening are supporting the chemiluminescence immunoassay market by increasing the volume and frequency of routine diagnostic testing performed across healthcare settings. Screening programs depend on laboratory tests to identify relevant biomarkers and support the early assessment of potential disease conditions. Continued emphasis on preventive healthcare and disease detection encourages regular testing among patient populations, increasing the utilization of immunoassay systems within diagnostic laboratories.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of infectious and chronic diseases driving demand for advanced diagnostic testing | 2.20% | High | North America, Asia Pacific | High | Near Term |
| Expanding hospital laboratory automation increasing adoption of high-throughput immunoassay platforms | 1.80% | High | North America, Europe | High | Mid Term |
| High diabetes and cancer screening rates boosting routine diagnostic testing volumes globally | 1.60% | High | Asia Pacific, Europe | High | Near Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America led the chemiluminescence immunoassay market, holding a 43.14% share in 2026, supported by advanced healthcare infrastructure, widespread adoption of automated diagnostic technologies, and substantial demand for high-throughput laboratory testing. The region benefits from strong integration of immunodiagnostic platforms across hospitals, clinical laboratories, and research settings, while continued investment in precision diagnostics and laboratory automation is reinforcing market development. In addition, a well-established biotechnology and pharmaceutical ecosystem supports the use of sensitive and efficient immunoassay technologies across clinical and research applications.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing region in the chemiluminescence immunoassay market, propelled by expanding healthcare infrastructure, increasing diagnostic testing requirements, and greater access to advanced laboratory technologies. Rising healthcare expenditure and the modernization of hospitals and diagnostic facilities are creating favorable conditions for automated immunoassay adoption. Growing awareness of early disease detection, increasing laboratory capacity, and efforts to improve diagnostic efficiency are further strengthening demand, particularly as healthcare systems across the region continue to expand and upgrade their testing capabilities.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Laboratory Automation IntegrationGermany emphasizes chemiluminescence immunoassay solutions that strengthen laboratory automation, workflow efficiency, and diagnostic consistency. Clinical laboratories in Germany increasingly adopt integrated analyzers supporting broad testing menus and standardized diagnostic processes.
France 🇫🇷
Specialty Diagnostic ExpansionFrance strengthens the use of chemiluminescence immunoassays in endocrine, infectious disease, and oncology diagnostics. Laboratories across France continue investing in flexible testing platforms that enhance clinical decision-making through dependable analytical performance.
Italy 🇮🇹
Routine Testing EfficiencyItaly prioritizes chemiluminescence immunoassay systems that improve efficiency in hospital laboratories and regional diagnostic networks. Healthcare facilities in Italy seek scalable analyzers capable of supporting diverse testing requirements while optimizing laboratory resource utilization.
Japan 🇯🇵
Precision Clinical TestingJapan focuses on chemiluminescence immunoassay technologies that deliver sensitive and reproducible diagnostic results across routine and specialized testing. Healthcare institutions in Japan prioritize compact automated systems that improve laboratory productivity while maintaining analytical reliability.
South Korea 🇰🇷
Digital Laboratory WorkflowsSouth Korea expands chemiluminescence immunoassay adoption through digitally connected laboratories and advanced clinical diagnostics. Healthcare providers in South Korea value automated analyzers that improve turnaround times and support efficient management of growing diagnostic workloads.
United States 🇺🇸
High-Throughput DiagnosticsThe U.S. chemiluminescence immunoassay market prioritizes automated diagnostic platforms capable of processing large testing volumes with consistent analytical performance. Healthcare providers in the U.S. continue integrating advanced immunoassay systems into routine clinical laboratory operations.
Segment Leadership and Growth Trends
Chemiluminescence Immunoassay Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Consumables (Largest & Fastest-Growing Segment)
The consumables segment held the largest share of the chemiluminescence immunoassay market at 64.21% in 2026 and also represented the fastest-growing segment. Its leading position reflects the recurring requirement for reagents, assay kits, and other consumable components used in chemiluminescence immunoassay workflows. These products are essential for routine diagnostic testing and support a wide range of clinical applications, creating sustained demand alongside testing activity. Increasing adoption of automated immunoassay platforms, the need for efficient high-throughput diagnostics, and continued emphasis on accurate laboratory testing are further strengthening the importance of consumables within the market.
Sample Type Segment Analysis: Blood (Largest Segment) vs Urine (Fastest-Growing Segment)
Blood samples accounted for the largest share of the chemiluminescence immunoassay market at 58.59% in 2026, supported by their extensive use in clinical diagnostics and laboratory-based assessment of biomarkers, hormones, infectious diseases, and other health conditions. Blood testing provides access to a broad range of clinically relevant analytes, making it a fundamental sample type for immunoassay workflows. Growing demand for sensitive diagnostic testing and the increasing use of immunoassays for disease screening and monitoring continue to reinforce the dominance of blood-based applications.
The urine sample segment is the fastest-growing segment, benefiting from the expanding use of non-invasive and convenient specimen types in diagnostic workflows. Urine can provide clinically relevant information for evaluating metabolic, hormonal, renal, and other health-related conditions while offering a relatively accessible method of sample collection. Continued development of sensitive assay technologies and growing interest in simpler diagnostic procedures are supporting broader integration of urine samples into immunoassay-based testing.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Instruments, Consumables, Software & Services | Consumables | Consumables |
| Sample Type | Blood, Urine, Saliva, Others | Blood | Urine |
| End-use | Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Others | Hospitals | Pharmaceutical & Biotechnology Companies |
| Application | Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease, Autoimmune Disease, Others | Infectious Disease | Oncology |
Competitive Landscape and Market Positioning
Major players in the chemiluminescence immunoassay market:
1. Abbott Laboratories (United States)
2. F. Hoffmann-La Roche AG (Switzerland)
3. Siemens Healthineers AG (Germany)
4. Danaher Corporation (United States)
5. DiaSorin S.p.A. (Italy)
6. Shenzhen Mindray Bio-Medical Electronics Co. Ltd. (China)
7. Sysmex Corporation (Japan)
8. bioMérieux SA (France)
9. QuidelOrtho Corporation (United States)
Rapid advancements in diagnostic sensitivity and laboratory automation are reshaping the chemiluminescence immunoassay market. Manufacturers are introducing next-generation assay platforms with faster processing capabilities, improved analytical precision, and expanded disease detection applications to address growing demand for high-throughput diagnostic solutions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| F. Hoffmann-La Roche AG (Switzerland) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Danaher Corporation (United States) | |||||||
| DiaSorin S.p.A. (Italy) | |||||||
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd. (China) | |||||||
| Sysmex Corporation (Japan) | |||||||
| bioMérieux SA (France) | |||||||
| QuidelOrtho Corporation (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| ALZpath, Inc. | Dec-25 | ALZpath, Inc. entered a licensing agreement with Siemens Healthineers to incorporate its proprietary pTau217 antibody into Siemens' expanding menu of in vitro diagnostic (IVD) tests for Alzheimer's disease. This strategic collaboration enhances the clinical utility of Siemens’ immunoassay platforms by providing high-precision tools for earlier and more accurate detection of dementia-related biomarkers. |
| Abbott | Nov-25 | Abbott completed a definitive agreement to acquire Exact Sciences for approximately USD 21 billion in equity value. This major strategic entry into the oncology diagnostics market provides Abbott with a comprehensive portfolio of cancer screening and precision diagnostics, including liquid biopsy and molecular residual disease (MRD) testing technologies, significantly expanding its footprint in the multi-billion dollar cancer testing segment. |
| Roche | Oct-25 | Roche received CE Mark approval for its Elecsys Dengue Ag test, a high-throughput, fully automated immunoassay. Designed to support the rapid diagnosis of acute dengue virus infections, the test leverages Roche’s established diagnostic infrastructure to provide clinical labs with scalable, automated solutions for managing large-scale disease surveillance and patient care in endemic regions. |
| AB ANALITICA | Sep-24 | AB ANALITICA formed a distribution partnership with SNIBE to commercialize the SNIBE Molecision R8 platform in Italy. The agreement integrates automated immunodiagnostic and molecular testing capabilities, enabling laboratories to streamline complex diagnostic workflows and improving local access to advanced assays for infectious disease and oncology research. |
| Sysmex | Dec-22 | Sysmex received approval in Japan for the manufacturing and marketing of its HISCL β-Amyloid 1-42 and 1-40 Assay Kits. These assays are designed for the precise detection of amyloid beta levels in blood samples, marking a significant advancement in the development of accessible, blood-based diagnostic tools for the early identification and clinical management of Alzheimer’s disease. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Chemiluminescence Immunoassay Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Test Throughput | Low-Throughput Systems, Medium-Throughput Systems, High-Throughput Systems |
| Automation Level | Manual Systems, Semi-Automated Systems, Fully Automated Systems |
| Purchasing Channel | Direct Manufacturer Sales, Distributor & Dealer Sales, Group Purchasing & Institutional Procurement |
Chemiluminescence Immunoassay Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Diagnostic Workflow Transformation Assessment |
|
| Laboratory Automation Opportunity Analysis |
|
| Decentralized Diagnostics Expansion Study |
|
Need a different cut of the data?
Request Custom ResearchHow large is the chemiluminescence immunoassay market?
What is the expected industry size of chemiluminescence immunoassay by 2036?
Why is laboratory automation accelerating adoption in the chemiluminescence immunoassay market?
How are routine disease screening programs supporting market growth?
What makes Consumables the leading product segment in the chemiluminescence immunoassay market?
Why is Urine the fastest-growing sample type in the chemiluminescence immunoassay market?
Why is North America the leading region for chemiluminescence immunoassay adoption?
What is driving Asia Pacific growth in the chemiluminescence immunoassay market?
Who holds a significant market share in the chemiluminescence immunoassay landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization